HIV Prevention and Alcohol (R34 Clinical Trials Optional)

The Funding Opportunity Announcement (FOA) for HIV Prevention and Alcohol (R34 Clinical Trials Optional) aims to strengthen HIV/AIDS prevention strategies among populations impacted by diverse patterns of alcohol usage. It seeks to comprehend and address the behavioral and biological risks linked with HIV acquisition in line with effective prevention and treatment interventions.

The initiative will facilitate research to minimize the incidence of new infections through a comprehensive understanding of reducing HIV. This R34 FOA supports studies that are essential in informing the planning of a clinical trial within the companion announcement of HIV Prevention and Alcohol (R01 Clinical Trials Optional).

Applicants for this grant should outline the intended clinical trial, demonstrating the scientific necessity of the suggested research in designing a subsequent trial (R34). This FOA is focused on research projects engineered to yield sufficient results to guide the future trial without requiring further studies.

The planned Phase II, III, or IV trial must primarily aim to confirm the efficacy, safety, and clinical management of the proposed intervention(s) in HIV prevention. This National Institute on Alcohol Abuse and Alcoholism (NIAAA) funding opportunity for pilot clinical trials through the R34 mechanism seeks to generate new insights that address a scientific question or operational issue. This could potentially influence the final development and testing of intervention tools in a clinical trial.